ArticleMolecular and cellular biology1993
Control of calcitonin/calcitonin gene-related peptide pre-mRNA processing by constitutive intron and exon elements.
Article in Molecular and cellular biology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 68 citations in OpenAlex.
- Phytochrome Coordinates with a hnRNP to Regulate Alternative Splicing via an Exonic Splicing Silencer.Plant physiology · 2020Article
- The mechanisms of a mammalian splicing enhancer.Nucleic acids research · 2018Article
- Genome-wide analysis of light-regulated alternative splicing mediated by photoreceptors in Physcomitrella patens.Genome biology · 2014Article
- A novel intronic cis element, ISE/ISS-3, regulates rat fibroblast growth factor receptor 2 splicing through activation of an upstream exon and repression of a downstream exon containing a noncanonical branch point sequence.Molecular and cellular biology · 2005Article
- Both U2 snRNA and U12 snRNA are required for accurate splicing of exon 5 of the rat calcitonin/CGRP gene.RNA (New York, N.Y.) · 2004Article
- Alternative splicing of U12-dependent introns in vivo responds to purine-rich enhancers.RNA (New York, N.Y.) · 2001Article
- Control of hnRNP A1 alternative splicing: an intron element represses use of the common 3' splice site.Molecular and cellular biology · 2000Article
- Requirements for mini-exon inclusion in potato invertase mRNAs provides evidence for exon-scanning interactions in plants.RNA (New York, N.Y.) · 2000Article
- An exonic splicing silencer in the testes-specific DNA ligase III beta exon.Nucleic acids research · 2000Article
- Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis.Microbiology and molecular biology reviews : MMBR · 1999Review
- CA- and purine-rich elements form a novel bipartite exon enhancer which governs inclusion of the minute virus of mice NS2-specific exon in both singly and doubly spliced mRNAs.Molecular and cellular biology · 1999Article
- Purine-rich enhancers function in the AT-AC pre-mRNA splicing pathway and do so independently of intact U1 snRNP.RNA (New York, N.Y.) · 1998Article
- Enhancer elements activate the weak 3' splice site of alpha-tropomyosin exon 2.RNA (New York, N.Y.) · 1998Article
- A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- An RNA splicing enhancer-like sequence is a component of a splicing inhibitor element from Rous sarcoma virus.Molecular and cellular biology · 1998Article
- A short sequence within two purine-rich enhancers determines 5' splice site specificity.Molecular and cellular biology · 1998Article
- Regulation of sex-specific selection of fruitless 5' splice sites by transformer and transformer-2.Molecular and cellular biology · 1998Article
- Functional crosstalk between exon enhancers, polypyrimidine tracts and branchpoint sequences.The EMBO journal · 1997Article
- Control of alternative pre-mRNA splicing by distributed pentameric repeats.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production.Journal of virology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The calcitonin/calcitonin gene-related peptide (CGRP) primary transcript is alternatively spliced in thyroid C cells and neurons, resulting in the tissue-specific production of calcitonin and CGRP mRNAs. Analyses of mutated calcitonin/CGRP transcription units in permanently transfected cell lines have indicated that alternative splicing is regulated by a differential capacity to utilize the calcitonin-specific splice acceptor. The analysis of an extensive series of mutations suggests that tissue-specific regulation of calcitonin mRNA production does not depend on the presence of a single, unique cis-active element but instead appears to be a consequence of suboptimal constitutive splicing signals. While only those mutations that altered constitutive splicing signals affected splice choices, the action of multiple regulatory sequences cannot be formally excluded. Further, we have identified a 13-nucleotide purine-rich element from a constitutive exon that, when placed in exon 4, entirely switches splice site usage in CGRP-producing cells. These data suggest that specific exon recruitment sequences, in combination with other constitutive elements, serve an important function in exon recognition. These results are consistent with the hypothesis that tissue-specific alternative splicing of the calcitonin/CGRP primary transcript is mediated by cell-specific differences in components of the constitutive splicing machinery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.